EUVIMEDAtklāt EUVIMED
Übersichtsarbeit

New Roles of Artemisinins in Atherosclerosis Progression

Hamidreza Majidiani, Maryam Musavi, Amir Abbas Momtazi-Borojeni iD

Phytotherapy Research · 2025-04 · 39 (4) · 1847-1857

DOI: 10.1002/ptr.8483 ↗

At a glance

Übersichtsarbeit in Phytotherapy Research, published online on 2025-04-08. Written by Hamidreza Majidiani and 2 co-authors. Institution: Department of Basic Medical Sciences, Faculty of Medicine, Neyshabur University of Medical Sciences, Neyshabur, Iran. Major MEDLINE topics: Atherosclerosis, Artemisinins. Cited 8 times so far (Crossref); 94 references.

AbstraktsSubjectsBibliogrāfiskie datiCiteRelated studies

Abstract (original language)

Artemisinin is a natural compound derived from the Chinese plant Artemisia annua , which was officially approved by the FDA for its antimalarial effects. In recent years, a growing body of studies has shown the novel function of artemisinin in atherosclerosis therapy. In vivo studies have shown that artemisinin can inhibit the progression of atherosclerosis plaque. In the present review, the evidence showing the inhibitory effects of artemisinin on the progression of atherosclerosis plaque and its underlying mechanisms is discussed. Mechanistically, artemisinin and its derivatives act by modulating various atherosclerosis‐mediating risk factors, including hyperlipidemia, inflammation, oxidative stress, and malfunctioning vascular smooth muscle cells (VSMCs). Notably, artesunate, but not artemisinin, can attenuate the plasma levels of TG, TC, VLDL‐C, and LDL‐c, along with a substantial decline in arterial lipid deposition through enhancing the LDPL activity via inducing the KFL2/NRF2/TCF7L2 axis. Artemisinin was found to ameliorate the atherosclerosis plaque inflammation by reducing monocyte adhesion and subsequent transmigration to the intima, via inhibiting the expression of ICAM‐1 and VCAM‐1, diminishing NLRP3 inflammasome activation, and reducing the expression of inflammatory factors such as IL‐1β, IL‐18, TNF‐α, MCP‐1, and TGF‐β1 mechanistically and mainly via suppressing the by NF‐κB activity. Artemisinin could exert antioxidant effects through activating the PI3K/Akt/eNOS signaling pathway and suppressing the ROS‐mediated NF‐κB signal pathway. Artemisinin could also improve the VSMC function in the atherosclerosis plaque. These findings can suggest artemisinin as a new therapeutic agent for treating atherosclerosis; however, future clinical trials are warranted to validate its therapeutic efficiency in patients with atherosclerosis.

Subjects

MeSH terms (MEDLINE)

AtherosclerosisArtemisininsHumansAnimalsOxidative StressDisease ProgressionPlaque, AtheroscleroticInflammationMuscle, Smooth, VascularSignal Transduction

Author keywords

artemisininatherosclerosishyperlipidemiamalaria

Substances

Artemisininsartemisinin

Authors and institutions

  • Department of Basic Medical Sciences, Faculty of Medicine, Neyshabur University of Medical Sciences, Neyshabur, Iran.
  • Department of Medical Biotechnology, School of Medicine, Neyshabur University of Medical Sciences, Faculty of Medicine,Neyshabur University of Medical Sciences, Neyshabur, Iran.

ORCID profiles: Amir Abbas Momtazi-Borojeni

Cite

APA

Majidiani, H., Musavi, M., & Momtazi-Borojeni, A. A. (2025). New Roles of Artemisinins in Atherosclerosis Progression. Phytotherapy Research, 39(4), 1847-1857. https://doi.org/10.1002/ptr.8483

Vancouver

Majidiani H, Musavi M, Momtazi-Borojeni AA. New Roles of Artemisinins in Atherosclerosis Progression. Phytotherapy Research. 2025;39(4):1847-1857. doi:10.1002/ptr.8483

BibTeX
@article{Majidiani2025,
  author = {Majidiani, Hamidreza and Musavi, Maryam and Momtazi-Borojeni, Amir Abbas},
  title = {New Roles of Artemisinins in Atherosclerosis Progression},
  journal = {Phytotherapy Research},
  year = {2025},
  volume = {39},
  number = {4},
  pages = {1847--1857},
  doi = {10.1002/ptr.8483}
}
Start for free →